Compare PXLW & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXLW | CVM |
|---|---|---|
| Founded | 1997 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.5M | 43.3M |
| IPO Year | 2000 | 1987 |
| Metric | PXLW | CVM |
|---|---|---|
| Price | $6.41 | $6.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | ★ 85.6K | 63.9K |
| Earning Date | 02-11-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,205,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.67 | $1.98 |
| 52 Week High | $15.42 | $20.41 |
| Indicator | PXLW | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 56.77 |
| Support Level | $6.33 | $4.90 |
| Resistance Level | $7.15 | $6.56 |
| Average True Range (ATR) | 0.40 | 0.63 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 12.93 | 73.13 |
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.